Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed: 18,156
Companies: 1,062
Drugs tracked: 3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources

Quick answer

nintedanib, Nintedanib, nintedanib

A Phase II, 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in patients with major depressive disorder

BI 1810631

BI 1815368, BI 1815368 Placebo, BI 1815368

BI 1819479, Placebo, Film-coated tablet, matching in size, weight, colour and shape to BI 1819479 (both unit strengths), BI 1819479

BI 1839100, Placebo matching in size, weight, colour and shape to tablets of BI 1839100

BI 3000202, BI 3000202, Placebo matching BI 3000202

BI 3720931, BI 3720931

BI 3720931, Gadovist 1.0 mmol/ml solution for injection, Solvent for dilution for BI 3720931 inhaler solution, BI 3720931

BI 685509, Placebo matching BI 685509 PRD9566383, Placebo matching BI 685509 PRD9566375, BI 685509, BI 685509, Placebo matching BI 685509 PRD9566374

BI 690517, Jardiance 10 mg film-coated tablets, Placebo matching vicadrostat

BI 764198, Placebo to match BI 764198, BI 764198, BI 764198

BI 764524, Sham Injection Procedure

BI 907828, BI 907828, BI 907828

Matching placebo tablets without active substance, BI 706321, BI 706321, BI 706321, STELARA 130 mg concentrate for solution for infusion, STELARA 90 mg solution for injection in pre-filled pen

Pemetrexed EVER Pharma 25 mg/ml concentrate for solution for infusion, BI 1810631, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion.

Placebo matching BI 764198, BI 764198

Placebo to BI 765423, BI 765423

Spesolimab

"A study in healthy people to test how 2 different formulations of a combination treatment (vicadrostat and empagliflozin) are taken up in the body and how food influences the amount of the medicines in the blood"

"A study to test how well BI 3000202 is tolerated by people with type 1 interferonopathies"

A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

A study in healthy men and women to test how BI 3000202 is taken up and processed by the body

Frequently asked questions